Psychiatric Adverse Events in Randomized, Double-Blind, Placebo-Controlled Clinical Trials of Varenicline
- 1 April 2010
- journal article
- research article
- Published by Springer Science and Business Media LLC in Drug Safety
- Vol. 33 (4), 289-301
- https://doi.org/10.2165/11319180-000000000-00000
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research DatabaseBMJ, 2009
- Mood, Side-effects and Smoking Outcomes Among Persons With and Without Probable Lifetime Depression Taking VareniclineJournal of General Internal Medicine, 2009
- A Preliminary Benefit-Risk Assessment of Varenicline in Smoking CessationDrug Safety, 2009
- Neuropsychiatric disturbance after initiation of varenicline in a patient with a history of alcohol abuse and major depressionAmerican Journal of Health-System Pharmacy, 2008
- Varenicline in the routine treatment of tobacco dependence: a pre–post comparison with nicotine replacement therapy and an evaluation in those with mental illnessAddiction, 2007
- Exacerbation of Schizophrenia by VareniclineAmerican Journal of Psychiatry, 2007
- Pharmacological profile of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aidNeuropharmacology, 2007
- Antidepressants for smoking cessationPublished by Wiley ,2006
- Efficacy of Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Placebo or Sustained-Release Bupropion for Smoking CessationA Randomized Controlled TrialJAMA, 2006
- Neuroadaptations to chronic exposure to drugs of abuse: Relevance to depressive symptomatology seen across psychiatric diagnostic categoriesNeurotoxicity Research, 2002